Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

United Therapeutics Settles Federal Kickback Lawsuit for $210 Million

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:Drug Industry Daily

United Therapeutics agreed to pay $210 million to resolve Justice Department claims that the drugmaker collaborated with charity Caring Voice Coalition (CVC) to boost sales of United’s pulmonary arterial hypertension…

Continue ReadingUnited Therapeutics Settles Federal Kickback Lawsuit for $210 Million

FDA Reminds Sponsors to Submit One-Time Orange Book Status Report

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:Drug Industry Daily

The FDA is requesting all NDA and ANDA holders to submit a one-time, written status report to the agency after reviewing the information published in the Orange Book. Source: Drug…

Continue ReadingFDA Reminds Sponsors to Submit One-Time Orange Book Status Report

FDA Finalizes Guidance on Biowaivers and Biopharmaceutical Classification

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:Drug Industry Daily

The FDA finalized its May 2015 guidance on how makers of immediate-release, solid, oral products can request waivers for subsequent in vivo bioavailability and bioequivalence studies. Source: Drug Industry Daily

Continue ReadingFDA Finalizes Guidance on Biowaivers and Biopharmaceutical Classification

Senators Seek Clarity on FDA’s Canadian Drug Importation Policy

  • Post author:Sam
  • Post published:December 26, 2017
  • Post category:Drug Industry Daily

Sens. Chuck Grassley (R-Iowa) and Amy Klobuchar (D-Minn.) asked FDA Commissioner Scott Gottlieb in a Dec. 18 letter to clarify the agency’s policies on importing prescription drugs from Canada. Source:…

Continue ReadingSenators Seek Clarity on FDA’s Canadian Drug Importation Policy

FDA Targets Generic Approvals, Drug Pricing for 2018

  • Post author:Sam
  • Post published:December 25, 2017
  • Post category:Drug Industry Daily

Faster approvals of generics and biosimilars, along with other measures aimed at reducing prescription drug prices, will be ongoing FDA priorities in 2018. Source: Drug Industry Daily

Continue ReadingFDA Targets Generic Approvals, Drug Pricing for 2018

What’s Ahead for 2018?

  • Post author:Sam
  • Post published:December 25, 2017
  • Post category:Drug Industry Daily

In this issue of Drug Industry Daily, we examine some of the FDA’s priorities for 2018 and what industry experts expect to happen. We already know the FDA’s priorities for…

Continue ReadingWhat’s Ahead for 2018?

EMA Juggling Brexit and New Quality and Safety Guidelines for 2018

  • Post author:Sam
  • Post published:December 25, 2017
  • Post category:Drug Industry Daily

In 2018, the European Medicines Agency’s quality and safety working groups intend to tackle several new guidelines, covering the sterilization of products and containers, risk-based prevention of cross contamination in…

Continue ReadingEMA Juggling Brexit and New Quality and Safety Guidelines for 2018

FDA Plans to Expedite Product Reviews by Hiring More Staff

  • Post author:Sam
  • Post published:December 25, 2017
  • Post category:Drug Industry Daily

The FDA hopes to bolster its scientific staff in 2018 — not only to expedite product reviews, but to meet its commitments to industry under the user fee agreements —…

Continue ReadingFDA Plans to Expedite Product Reviews by Hiring More Staff

Experts See Use of Real-World Evidence as a Key Clinical Trial Trend

  • Post author:Sam
  • Post published:December 25, 2017
  • Post category:Drug Industry Daily

The FDA’s use of real-world evidence in regulatory decision-making and further implementation of the 21st Century Cures Act are the biggest trends in clinical trials to track in 2018, according…

Continue ReadingExperts See Use of Real-World Evidence as a Key Clinical Trial Trend

Data Integrity Will be FDA’s Focus for Quality

  • Post author:Sam
  • Post published:December 25, 2017
  • Post category:Drug Industry Daily

Quality experts and FDA officials predict 2018 will bring more streamlined FDA inspections and a greater focus on digital records and data integrity, as the agency implements its ambitious Concept…

Continue ReadingData Integrity Will be FDA’s Focus for Quality
  • Go to the previous page
  • 1
  • …
  • 278
  • 279
  • 280
  • 281
  • 282
  • 283
  • 284
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.